The interactions between inflammation and coagulation

被引:884
作者
Esmon, CT
机构
[1] Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA
[3] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA
[4] Howard Hughes Med Inst, Oklahoma City, OK USA
关键词
protein C pathway; thrombosis; sepsis; inflammation; vascular biology;
D O I
10.1111/j.1365-2141.2005.05753.x
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Inflammation initiates clotting, decreases the activity of natural anticoagulant mechanisms and impairs the fibrinolytic system. Inflammatory cytokines are the major mediators involved in coagulation activation. The natural anticoagulants function to dampen elevation of cytokine levels. Furthermore, components of the natural anticoagulant cascades, like thrombomodulin, minimise endothelial cell dysfunction by rendering the cells less responsive to inflammatory mediators, facilitate the neutralisation of some inflammatory mediators and decrease loss of endothelial barrier function. Hence, downregulation of anticoagulant pathways not only promotes thrombosis but also amplifies the inflammatory process. When the inflammation-coagulation interactions overwhelm the natural defence systems, catastrophic events occur, such as manifested in severe sepsis or inflammatory bowel disease.
引用
收藏
页码:417 / 430
页数:14
相关论文
共 128 条
[1]
The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism [J].
Abeyama, K ;
Stern, DM ;
Ito, Y ;
Kawahara, K ;
Yoshimoto, Y ;
Tanaka, M ;
Uchimura, T ;
Ida, N ;
Yamazaki, Y ;
Yamada, S ;
Yamamoto, Y ;
Yamamoto, H ;
Iino, S ;
Taniguchi, N ;
Maruyama, I .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (05) :1267-1274
[2]
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[3]
STRUCTURALLY HOMOLOGOUS LIGAND-BINDING OF INTEGRIN MAC-1 AND VIRAL GLYCOPROTEIN-C RECEPTORS [J].
ALTIERI, DC ;
ETINGIN, OR ;
FAIR, DS ;
BRUNCK, TK ;
GELTOSKY, JE ;
HAJJAR, DP ;
EDGINGTON, TS .
SCIENCE, 1991, 254 (5035) :1200-1202
[4]
ALTIERI DC, 1988, J BIOL CHEM, V263, P7007
[5]
ADHESIVE RECEPTOR MAC-1 COORDINATES THE ACTIVATION OF FACTOR-X ON STIMULATED CELLS OF MONOCYTIC AND MYELOID DIFFERENTIATION - AN ALTERNATIVE INITIATION OF THE COAGULATION PROTEASE CASCADE [J].
ALTIERI, DC ;
MORRISSEY, JH ;
EDGINGTON, TS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (20) :7462-7466
[6]
CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism [J].
André, P ;
Prasad, KSS ;
Denis, CV ;
He, M ;
Papalia, JM ;
Hynes, RO ;
Phillips, DR ;
Wagner, DD .
NATURE MEDICINE, 2002, 8 (03) :247-252
[7]
Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism [J].
Baglin, TP ;
Carrell, RW ;
Church, FC ;
Esmon, CT ;
Huntington, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) :11079-11084
[8]
TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex [J].
Bajzar, L ;
Morser, J ;
Nesheim, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16603-16608
[9]
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[10]
Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709